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The authors describe the interactions between and the differential effects of carbamazepine
and individual psychotherapy in the treatment of a schizoaffective patient. Carbamazepine's
impact on the patient's affective life facilitated the establishment of a working alliance in
psychotherapy. As the patient began to understand and differentiate aspects of his affective,
cognitive, bodily, and interpersonal experiences, his life situation stabilized and his carbamaze-
pine dose requirements diminished.
INTRODUCTION
During the past fifteen years, several authors have described the effects of
carbamazepine on human behaviors [1-8]. Ballenger and Post studied the use of
carbamazepine in patients with affectivedisorders anddemonstrated its antimanic and
prophylactic effects in patients with bipolar disorders [7]. Carbamazepine's antide-
pressant effects are less clearly documented [7]. Lipinski and Pope noted that lithium
and carbamazepine may act synergistically in manic patients who have had a poor
response to lithium alone [9]. There is also an extensive literature which explores the
relationship between drugs and psychotherapy in the treatment ofaffective disorders,
particularly depression [10-12]. To our knowledge there have been no case reports or
controlled studies that have attempted to delineate the relationship between carbama-
zepine and psychological or social interventions in the treatment oflithium-refractory
bipolar or schizoaffective patients.
Several years ago we began working with a young male schizoaffective patient,
whose renal functioning had been severely compromised in association with prolonged
lithium therapy [13]. He refused carbamazepine for a year but has been on the drug
since 1980. This case report describes the interactions between and the differential
effects of carbamazepine and his individual psychotherapy during the course of his
inpatient treatment.
BriefCase History
Adam is a 33-year-old man, whose fourteen-year psychiatric history raises compli-
cated diagnostic issues [14]. His clinical course is most consistent with a schizoaffec-
tive disorder, and it has been characterized by the initial appearance of depression
followed bymultiplehospitalizations for mania, aswell asevidenceofa formal thought
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disorder both in the presence and in the absence ofan affective syndrome. The patient
was the only male child in a wealthy family with four children. His birth and early
childhood years were uneventful, except that he was noted to have Gilbert's disease.
During latency Adam noted that his affective responses to stressful situations differed
from those ofothers in his family. Forexample, when hisdogdied Adam stated, "I had
no feelings at all." There was no history of psychomotor seizures. There was no
documented family history of psychosis, affective disorder, alcoholism, seizures, or
renal disease. Mother doted on her son yet related to him in a superficial, infantilizing,
and controlling manner. Father attempted to protect his wife from emotional stresses
and to maintain an outward appearance of family harmony. Adam experienced
progressive alienation, self-doubt, and depression during high school. He also experi-
enced brief periods of derealization and depersonalization but told no one of these
symptoms. He left college during his junior year in a severe depression characterized
by withdrawal and despair. During the next few years, depressive periods lasted from
several weeks to months, alternating with months ofhypomanic activity.
In the first of 16 hospitalizations Adam was admitted in a manic state and was
begun on lithium. Over the ensuing eight years (1971-1978) his lithium blood levels
averaged 1.5 mmol per liter. Adam's hospitalizations were usually precipitated by
violent and psychoticbehaviors, includingmania, ranging induration from a fewweeks
to several months. His compliance with lithium treatment as an outpatient was
uncertain. When hospitalized for mania, Adam often required high doses of antipsy-
chotic medication (chlorpromazine up to 3,500 mg per day) and seclusion during
periods ofpsychoticdecompensation. Although his manic symptoms usually responded
to lithium within a few weeks, on other occasions he remained manic for up to three
months. Prior to 1979, he had never received antidepressants.
In 1978 Adam had an open renal biopsywhich revealed chronicinterstitial nephritis.
His lithium level was 2.0 mmol per liter and his serum creatinine was 4.1 mg/100 ml at
the time ofhis biopsy. Eleven months earlier his serumcreatinine had been 2.0 mg/100
ml. A right retrograde pyelographic examination was negative. It is not clear whether
Adam had any evidence of renal dysfunction prior to the initiation of lithium
treatment. Lithium was discontinued prior to the biopsy, and high doses of antipsy-
chotic drugs were utilized during subsequent manic episodes which occurred each fall
and winter. Electroconvulsive treatment was not attempted, and there is no evidence
that psychological interventions were of any benefit. Evidence of early tardive
dyskinesia was noted in 1979.
Early Hospital Course
Adam was an inpatient at the Yale Psychiatric Institute (YPI) for three years
(1979-1982). The first seventeen monthsofhis hospitalization were marked by a series
of dramatic changes of clinical state, including assaultiveness, depression, suicidality,
and higher-level functioning. During this period, a series of medication changes were
ordered in response to changes in symptoms. The drugs utilized included thioridazine,
chlorpromazine, haloperidol, thiothixene, amitryptiline, and tryptophan. Adam was
also treated in individual, family, and group psychotherapy, although none of these
interventions appeared to have significant effect on the course ofillness. A number of
behavioral interventions were also attempted, including seclusion, restraints, and wet
packs. His admission diagnosis was bipolar disorder, mixed type. A sleep-deprived
electroencephalogram was unremarkable, and a CAT scan with contrast revealed no
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abnormalities. Serum creatinine levels ranged between 2.5 and 3.5 mg/100 ml,
creatinine clearance was 44 ml/minute, and treatment with lithium was contraindi-
cated. In the latter three months of this 17-month period, Adam became suicidally
depressed. There was no significant response to amitryptiline.
Carbamazepine andIndividual Psychotherapy
Although nearly three years oftreatment will be summarized, our report will focus
on an eight-month period, during which the patient was most symptomatic (July 1980
to February 1981). Since then, the patient's clinical course has been relatively smooth.
He has not had serious manic or depressive symptoms in four years, has been outofthe
hospital for nearly three years, has married, and works full time. He continues to be
involved in intensive individual psychotherapy and takes carbamazepine, 600 mg per
day (plasma level = 11.8, therapeutic range = 8-12 mcg/ml).
Adam was severely depressed when J.C. became his individual therapist (July
1980): "I have given up on life," and alternated between a glazed, withdrawn posture
and marked agitation. His thoughts wereoften blocked, and his speech was broken. He
felt hollow, inept, and was generally unresponsive to others. He also expressed a strong
fear of emergent homosexual feelings. He was fixated on the past and seemed to be
victimized by tormenting fragments ofmemories from childhood and early adulthood.
Carbamazepine was started three weeks after treatment began with J.C. The dose was
progressively increased from 200-600 mg per day over a ten-day period. No side
effects were observed, and a plasma level of9.0 mcg/ml was attained within 20 days.
The therapist began to intervene in Adam's depression, at first by acknowledging his
feelings of worthlessness and later by focusing on present thoughts and feelings,
including reactions to the therapist. The therapist later redirected Adam's focus to his
contact with others, particularly parents and peers. Both the therapist and the ward
staff attempted to bring a high degree of clarity and structure to their work with
Adam.
Adam's depression began lifting during the tenth week of therapy, coincident with
an increase in carbamazepine to 800 mg per day. Adam's carbamazepine plasma level
had dropped, and there was concern (because of past history) that he might become
hypomanic. It is not clear whether the lifting of Adam's depression was a drug effect,
related to his psychological treatments, to the natural course of his illness, or to some
combination ofthe above factors. He was able togo on trips outsidethe hospital for the
first time in over a year. By mid-October, however, mild elevations in Adam's mood
were apparent. Progressive increments in carbamazepine, up to 1,400 mg per day, led
to substantial stabilization in Adam's mood but did not lead to significant changes in
his drug levels. In therapy Adam seemed to take some distance from his hypomanic
symptoms, and Adam's struggles for independence became a focal point in therapy.
Once agan the therapist attempted to clarify and structure Adam's thoughts and
poorly differentiated affects.
As Adam's depression lifted he became more involved with staffand other patients,
and the therapist attempted to teach Adam to monitor momentary feelings. At first,
Adam found it difficult to monitor such feelings and often attempted to describe them
in metaphors or highly abstract analogies. He quickly learned, however, to articulate
his feelings in a more spontaneous and less contrived manner. Within a month, Adam
became more active and invested in floor activities. His thinking also seemed better
integrated. He began to experienced positive affect. The emergence ofpositive affects
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was, however, quickly followed by briefepisodes ofexpansive and grandiose thinking,
apparently in response tocompetitive, angry, andsexual feelings elicited in hiscontacts
with peers and staff. These episodes were also associated with his parents' extended
vacations. Unlike earlier experiences with mania, Adam described these episodes as
fleeting with a sense ofdetachment rather than enmeshment in his feelings: "Oh, I'm
having a crazy thought; isn't this interesting." He began to express overt anger for the
first time in a controlled nonmanic state, at first in a forced, defensive manner by
pronouncement and later in a more spontaneous fashion.
A significant decrease in the level ofagitation was observed during the third month
ofpsychotherapy and a reduction in anxietyduring thefourth monthofpsychotherapy.
The decrease in anxiety and an associated reduction in the level ofAdam's egocentric
thinkingappeared tohelpAdamto maintain an interest in his newtherapist, todevelop
a more substantial therapeutic alliance, and to better articulate his subjective
experience ofdepression.
In the next two months, Adam began to consider the long-standing conflict of
dependence/independence in relation to his parents. Adam wavered in his discussions
about his parents and others between autocratic pronouncements of his feelings and
thinking and greater appreciation of and yearning for mutuality. The therapist
encouraged him to consider the apparent egocentricity of his understanding and also
began to reconstruct a developmental scenario including Adam's style ofcoping with
threats to autonomy and the long-standing repression of affect. Consistent with an
earlier theme, Adam wasasked toconsider the realityofpersistentgrandiose notionsof
his competence, giftedness, and specialness (in periods in which he was notdepressed).
Toward the end of this period, he began to feel less anxious in the presence of others
and more confident ofhis ability to modulate his affective responses to others.
They don't know it yet [parents], but the war is over. Like Taras Bulba [the
movie], I'vejumped the chasm on my horse. Looking back, it doesn't seem like
such a big deal. It becomes more tolerable when you realize the game is the
chess board, rather than a single piece you're working on at any given
moment.
Adam did not require antipsychotic medication through the fall of 1980. His
hypomanic symptoms had responded well to carbamazepine and he worked effectively
both in psychotherapy and on the ward. Just before Christmas, however, a major
problem arose which threatened the success ofAdam's treatment. His blood pressure,
monitored since his admission, was in the borderline range (diastolic 85-90 mm Hg); it
began to increase significantly at times with diastolic readings of over 100. Higher
readings were often, but not always, associated with increased hypomanic activity.
Renal consultation was obtained, and we pursued the question ofwhether carbamaze-
pine caused elevated blood pressure. We learned that the drug manufacturer (Ciba
Geigy Pharmaceuticals) had records of only four or five anecdotal cases of elevated
blood pressure associated with its use [15]. In each case, the patient had a previous
history ofhypertension and the blood pressure returned to its pretreatment level when
the carbamazepine was discontinued. The drug manufacturer suggested that we stop
themedication. Thedrug wasdropped by 200 mg increments and, within fivedays, at a
plasma levelof5.0mcg/ml and adoseof 1,000 mg, Adam becameseverely hypomanic.
After consultation with our medical consultants and the family, the carbamazepine
dose was raised to 1,400 mg and within threedaysAdam's mood normalized. His blood
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pressure was stabilized with a regimen oflasix 80 mg/day, inderol 160 mg/day, and a
low-salt diet. Adam's creatinine clearance remained unchanged from admission
values.
The onset of this medical problem, coupled with the fact of Adam's parents and
individual therapist taking extended vacations, seemed to trigger the onset of brief
episodes ofmania. Duringonesuchepisode, Adamdeveloped a theory of"lunatricity":
"the energy lost when forces beyond one's control intrude and act upon one." The
clinical interventions in such episodes were:
1. increased dosage of carbamazepine from 400 mg three times daily to 1,400
mg/day
2. measured responses to pro- and antisocial behaviors, including greater
freedom and responsibility as well as briefperiods in seclusion
3. increased efforts to encourage expression of affect, particularly anger,
insecurity, and dependency
4. an effort to help Adam understand manic episodes as reactive within the
context ofa larger conflict over dependence/independence
Although it is clear that Adam experienced unmistakable periods of hypomania
during this period of his treatment, the duration ofthese episodes was brief. Also, the
settings and apparent stimuli for such episodes became clearer; Adam was extremely
sensitive to separations, to perceived challenges to his sense of independence and
autonomy, and to decreases in his carbamazepine dosage. Adam began to integrate
apparent psychotic levels of understanding, i.e., "lunatricity," with more substantial
forms of understanding, albeit overly symbolic and metaphorical. As a case in point,
the "principle" of lunatricity was subsequently integrated in a new metaphor for
Adam's understanding ofhuman relations:
I used to operate under the assumption that my universe was Ptolemaic-
everything revolved around me, my parents, and my friends. I now understand
that I need to understand things in relation to a Copernican universe. There are
multiple centers-my parents'are one, butonly one center toward which I must
relate a part ofmyself.
Thus a prolonged period of florid mania was averted by a conjoint management of
medication, cognitive controls, and behavioral contingencies. Adam was successful in
expressing anger toward his parents in a controlled manner for the first time in his
hospitalization and, according to Adam, for the first time in his life. The expression of
anger as a vehicle fordeveloping a sense ofseparateness from his parents began to lead
to a change in Adam's assumptions about relating to others.
Adam's carbamazepine dosage was stabilized at 1,400 mg per day and he became
more involved in ward activities, achieved greater freedom within the hospital, and
demonstrated less dramatic fluctuations in mood. He was urged to assume a greater
role in charting his own future and in asserting his independence.
His initial responses to this challenge were somewhat grandiose and adolescent. He
assumed the role ofa staffmember or the roleofan entitled patient who was above the
rules and regulations of the hospital. When confronted with the narcissistic and
egocentric quality of his behavior, he began to seek guidance from his therapist and
began to practice cooperation and mutuality. He expressed the wish to establish a
single and sustained romantic relationship with a female. He had translated a set of
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criteria for stability and mutuality (albeit in an artificial manner) from earlier
explanations ofthe requirements fora successful treatment plan; clearly, he had begun
to internalize a new set of criteria for his own life. Toward the end of this period, he
became active in planning an eventual transfer to a more open hospital environment.
This plan included working at ajob outside the hospital.
A standard psychological test battery was administered shortly after his move to the
open hospital environment. Despite considerable evidence ofhigher functioning and no
overt evidence of psychosis, testing indicated the presence of an underlying schizoaf-
fective psychosis with thought disorder, grandiosity, narcissistic character pathology,
and prominent themes of depression, anger, and disturbed sexuality. Testing also
indicated the presence of more reality-oriented defenses and adaptativeness, particu-
larly in more structured settings. The testing confirmed, then, the precarious nature of
Adam's recompensation and the need to continue a gradual, structured, and rational
treatment plan including: (1) continuation of long-term hospitalization; (2) continua-
tion ofpsychotherapy after hospitalization; (3) continuation ofmedical treatment with
carbamazepineand medication for blood pressure; and (4) creation and maintenanceof
structured plans for gradual assumption oflife outside the hospital.
DISCUSSION
Synergy Between Carbamazepine andPsychotherapy
Adam's treatment illustrates the importance of addressing all areas of a patient's
pathology in a systematic and integrated manner. It emphasizes the clinician's need to
view the patient from multiple perspectives, i.e., biological, familial, characterological,
and so on, and to maintain an ongoing awareness of the patient's strengths and
weaknesses. A variety of clinical interventions have been described; the choice and
timing of specific interventions affected particular aspects of the patient's clinical
course (e.g., carbamazepine to reduce manic symptoms).
Carbamazepine caused a rapid reduction in manic and hypomanic behaviors. It has
helped to prevent the eruption of major depressive or manic episodes for over four
years. Adam was quite depressed when carbamazepine was initiated. Although it
probably contributed to a reduction in his level of agitation, irritability, and anxiety
and facilitated accessibility to psychotherapeutic intervention, symptoms ofdepression
persisted for eight weeks after the drug was initiated. The patient's depression lifted
during the fall of 1980. Adam usually became hypomanic during autumn. Medication
coupled with the development of a solid working alliance in psychotherapy may have
contributed to his emergence from depression. The carbamazepine's impact on his
depression is unclear, but he had previously been inaccessible to psychotherapeutic
interventions during depressive periods.
Evidence of impending mania became apparent in the patient's psychotherapy
before manic behavior was noted on the ward. In addition, it was observed that a
decrease in Adam's carbamazepine blood level was associated with impending manic
activity. Carbamazepine dosages were raised rapidly in response to manic symptoms
during the first several months oftreatment. Increasing thecarbamazepine dose led to
increased drug levels and blocked or markedly reduced manic activity. Post et al. [16]
have noted that there is noconsistentcorrelation betweencarbamazepineplasma levels
and its clinical efficacy as a psychotropic agent, except that the therapeutic range
seemed similar to that necessary for anticonvulsant efficacy (6-12 mcg/ml). They
have, however, demonstrated that cerebrospinal fluid concentrations of carbamaze-
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pine's-10,11- epoxide metabolite correlate positively with the drug's antidepressant
effect [16]. Although we obtainedcarbamazepine plasma levels only, we observed that
Adam required carbamazepine levels in a high therapeutic range to block manic
symptoms; moreover, as he was becoming manic, his "carbamazepine space"
increased, i.e., it tookhigher doses to maintain agiven plasma level at that time. A like
phenomenon is seen with lithium treatment of manic patients.
Antipsychotic and antidepressant drugs were not used following the administration
ofcarbamazepine. Although there was no clear evidence that the drug demonstrated
anyantidepressant orantipsychotic effect in thispatient, Adam was more accessible in
therapy and on the ward during both psychotic and depressive periods. He seemed to
have more distance from his psychotic and depressive symptoms.
Adam's individual psychotherapy has focused on helping him to understand his
affective and cognitive experiences, making him aware of the severity of his illnesses
and teaching him to take responsibility for his medical care, teaching him about his
copingstyle under stress, increasing hisinterpersonal skills, and fostering autonomous
functioning. The therapist tried to help Adam organize, structure, and understand a
variety of internal and external events through clarification, confrontation, and
interpretation.
Adam seems to think moreclearly on the carbamazepine, and this has enhanced his
ability to utilizepsychotherapy. As his life situation has stabilized, including work and
a happy marriage, there has been no need to alter his carbamazepine dosage. Even
during the autumn, when Adam is at great risk for mania, his mood has remained
relatively stable and hiscarbamazpineplasma level has not fluctuated. Indeed, clinical
efficacy has been maintained with lower dose levels. This change might suggest that
the gains he has achieved in psychotherapy coupled with his increasingly stable life
style have reduced his vulnerability to mood swings. It must be recalled that Adam
experienced manicepisodes, at least yearly, during the nine years prior to carbamaze-
pine treatment. Since he has been on thisdrug, such symptoms have been transient and
readily controlled. To the extent that bothcarbamazepine and psychotherapy stabilize
various aspects of Adam's emotional and mental processes (biochemical vs. self-
awareness and improved interpersonal functioning) they act synergistically.
Issues in Psychotherapy
Bruch views the process of differentiation of the schizophrenic person as faulty,
"distorted and incomplete" [17: 347]. The patient has no sense of how to understand
his own behavior and that of others. Once the therapist has raised "the possibility of
establishing meaningful interpersonal communication" with the patient, several
therapeutic tasks emerge [17: 347]. These include: helping the patient to discover
"self-initiated behaviors," "unmasking areas of disturbed self awareness," and point-
ing out distortions in the patient's perception of the world [17: 348]. Careful
exploration and clarification of the patient's relationship to the therapist and of the
goals of therapy is central to this process [17]. This development of heightened
self-awareness and discovery is primarily an educational process, which involves the
patient's "becoming aware of bodily sensations and learning to correctly identify
different bodily states" [17: 350]. It also involves developing an awareness of the
relationship between changes in bodily sensations (e.g., in levels of energy) and the
patient's cognitive and affective experiences. The process of differentiation must
includethepropernamingofbodily,affective,cognitive, and interpersonal experiences
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as well as an understanding of how behaviors, affects, and thoughts originate (i.e., in
response to internal or external cues). Thus, the process of differentiation serves as a
first step toward organizing the patient's experiences. Adam's course in treatment may
be viewed along such a "differentiation continuum." Developmental elements in this
contiuum include: (a) differentiation of self-other; (b) differentiation of dependence-
independence; and (c) heightened self-awareness, understanding, and control over
bodily states, affects, and cognitive processes leading in turn to increasing control over
overt behaviors [17]. With increased awareness of and control over interpersonal
interactions and life in general, external control measures of an inpatient holding
environment such as physical restraints, wet packs, medication, and so on become less
necessary. Differentiation of experience ultimately leads to hierarchic integration and
finer regulation of experience.
Some patients, like Adam, with a biological element in their medical and psychiatric
illnesses, may require medication to aid in self-regulation indefinitely. As internal
states become more highly differentiated, clearly identified, and understood, however,
the extent to which chemical regulatory agents are needed by the patient may be
modified. In contrast to 1979 when he was unaware that he was experiencing
intensified biological processes which triggered his affective lability, Adam's current
heightened awareness of internal experiences may now allow him to exercise some
control over the intensity of these shifts. Indeed there have been fewer episodes of
hypomanic behavior and, most important, the patient seems better able to regulate his
energy level, affect, and behavior.
This is not to say that he does not require carbamazepine-he does. We are
suggesting that Adam's heightened self-awareness and control act synergistically with
the carbamazepine. Interestingly, this man who has clearly been psychotic, even when
not manic, has not required antipsychotic medication in four years. Without attempt-
ing to formulate a theory for this, exploration of the concept of "lunatricity" and its
evolution over time sheds some light on the way in which psychotic thought processes
may be modified over time.
Initially expressed as a condensed symbolic metaphor for then-current conflicts with
parents and increasing awareness of their influence in his life, the principle of
"lunatricity" was communicated to the therapist as a revelation. Adam believed that
he had uncovered a principle at least as important as the theory of relativity; he
considered himself to be a genius in the field of interpersonal communication. The
"principle" incorporated a number of associations including a visual perceptual
experience (the moon), a reference to his former home (which contains the syllable
-lun) and an evaluation of his present state (lunatic). As a principle, Adam incorpo-
rated a recent conflictual experience (attempting to communicate anger to his parents)
and a growing awareness of the past and present influence his parents have had in his
life.
The concept of "lunatricity" evolved slowly in the context of discussions of
egocentricity and narcissism. Originally a principle expressing the release of energy in
conflicted interpersonal situations, Adam twice revised the concept. In the first
revision, lunatricity referred to the energy available after the controlling factors in
interpersonal relationships had been discovered. In the second revision, lunatricity was
juxtaposed to a new metaphor. Relationships must be understood in a Galilean rather
than a Copernican universe; that is, controlling factors (people) do not derive from
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simple relationships between the son (sun) and parents. Parents are only one center.
People relate to multiple centers, e.g., friends, lovers, therapists, and the like. Whereas
Adam formerly believed that parents revolved around his life, he came to believe that
he interacted with a number of interpersonal centers. Therefore, the energy available
in complex interpersonal relationships can be isolated to particular centers ofactivity.
Several months later, Adam referred to the "principle" as an example of manic
thinking that combined experiences ofhis struggles with independence, creativity, and
inner control.
The evolution in the concept of lunatricity thus shows a progression from manic,
grandiose, and psychotic associations to ill-perceived conflicts, to the partial incorpora-
tion of a concept of more complex and stable interpersonal relations, to greater
differentiation and organization of interpersonal experience, to a reality-oriented
assessment ofhis own thinking. The progression reflects changes in Adam's metaphors
for his relationships with others, including issues of control, energy level, and reality
testing.
In the introduction to this paper the authors indicated that they wished to explore
the differential effects of psychotherapy and carbamazepine during the course of
Adam's treatment. In this discussion they have suggested that the more poorly
differentiated, the more disorganized, the more chaotic a person's internal life is, the
greater the need for external structure, control, and support in the patient's treatment.
During the case presentation it has been indicated that no amount of external
structure, support, or medication was of ongoing benefit to Adam prior to the use of
carbamazepine. Although it was felt that carbamazepine was critical for psychological
intervention, the fact that a change in psychotherapists occurred concurrent with its
use makes it difficult to determine how beneficial the drug really was for Adam.
Carbamazepine, in conjunction with a highly structured and clearly articulated series
of psychosocial interventions, led to an immediate reduction in Adam's anxiety,
however, and it allowed for the possibility of meaningful communication between
Adam and his therapist. The authors believe that the drug provided the initial control
necessary to regulate Adam's energy level, affective experience, behaviors, and
psychotic thoughts. Knowing that this type of control was available provided an
enormous degree ofsupport, reassurance, and hope to Adam, his therapist, his family,
and the hospital staff.
A developmental/historical perspective provided clear structure for Adam early in
therapy, facilitating organization of past memories, current experiences, and expecta-
tions for change. This structure provided Adam with a foreground (moment-by-
moment experience) and a background for understanding normal and abnormal
development ofthinking and affectivity. Focusing upon momentary affects, especially
in the context of the therapeutic transference, facilitated greater differentiation of
affectivity. Therapeutic interventions were increasingly perceived as helpful rather
than intrusive and controlling manipulations. Consistent efforts to foster an ability to
center and decenter hisexperience appear to havegiven himgreaterunderstanding and
control ofhis inner experiences, affects, and behaviors.
ACKNOWLEDGEMENTS
The authors wish to express their gratitude to Drs. Stephen Fleck and Charles Gardner for their helpful
suggestions during the preparation ofthis manuscript.
335336 CEGALIS AND POSSICK
REFERENCES
1. Marjerrison G, Jedlick SM, Keogh RP, et al: Carbamazepine: Behavioral, anticonvulsant, and EEG
effects in chronically hospitalized epileptics. Dis Nerv Syst 29:133-136, 1968
2. Pryse-Phillips WEM, Jeavens PM: Effects of carbamazepine (Tegretol) on the electroencephalogram
and ward behavior ofpatients with chronic epilepsy. Epilepsia 11:263-273, 1970
3. Dalby MA: Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of
psychomotor epilepsy. Epilepsia 12:325-334, 1971
4. Okuma T, Kishimoto A, Inoue K, et al: Anti-manic and prophylactic effects of carbamazepine on
manic-depressive psychosis. Folia Psychiatr Neurol Jpn 27:283-297, 1973
5. Monroe RR: Anticonvulsants in the treatment ofaggression. J Nerv Ment Dis 160:119-126, 1975
6. Okuma T, Kazutoyo I, Otsuki S, et al: Comparison of the antimanic efficacy of carbamazepine and
chlorpromazine: A double blind controlled study. Psychopharmacology 66:211-217, 1979
7. Ballenger JC, Post RM: Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry
137:782-790, 1980
8. Okuma T, Kazutoyo I, Otsuki S, et al: A preliminary double-blind study on the efficacy of
carbamazepine in prophylaxis ofmanic depressive illness. Psychopharmacology 73:95-96, 1981
9. Lipinski JF, Pope HG: Possible synergistic action between carbamazepine and lithium carbonate in the
treatment ofthree acutely manic patients. Am J Psychiatry 139:948-949, 1982
10. Docherty JP, Marder SR, Van Kammen DP, et al: Psychotherapy and pharmacotherapy: Conceptual
issues. Am J Psychiatry 134:529-533, 1977
11. Weissman MM: Psychotherapy and its relevance to the pharmacotherapy of affective disorders: from
ideology to evidence. In Psychopharmacology: A Generation of Progress. Edited by MA Lipton, A
DiMascio, KP Killam. New York, Raven Press, 1978
12. Karasu TB: Psychotherapy and pharmacotherapy: Toward an integrative model. Am J Psychiatry
139:1102-1113, 1982
13. Scully RE (ed): Case records ofthe Massachusetts General Hospital. New Eng J Med 304:1025-1032,
1981
14. Pope HG, Lipinski JF: Diagnosis in schizophrenia and manic depressive illness. Arch Gen Psychiatry
35:811-828, 1978
15. Givney P: Personal communication. February 1981
16. Post RM, Uhde TW, Ballenger JC, et al: Carbamazepine and its -10,11- epoxide metabolite in plasma
and CSF. Arch Gen Psychiatry 40:673-676, 1983
17. Bruch H: Psychotherapy with schizophrenics. Arch Gen Psychiatry 14:346-352, 1966